Picture of Biomarin Pharmaceutical logo

BMRN — Biomarin Pharmaceutical Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Momentum

Relative Strength (%)
1m-1.77%
3m+12.58%
6m+4.56%
1yr-14.86%
Volume Change (%)
10d/3m+27.65%
Price vs... (%)
52w High-5.92%
50d MA+0.63%
200d MA+7.54%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)180.65
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.73
Price to Tang. Book4.32
Price to Free Cashflow96.34
Price to Sales8.61
EV to EBITDA275.31

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-1.12%
Return on Equity-1.1%
Operating Margin-3.32%

Financial Summary

Year End 31st DecUnit201620172018201920202021E2022ECAGR / Avg
Total Revenue$m1,116.851,313.651,491.211,704.051,860.451,840.672,145.815.89%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/an/an/an/an/an/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for BMRN

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Biomarin Pharmaceutical EPS forecast chart

Profile Summary

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
October 25th, 1996
Public Since
July 21st, 2009
No. of Shareholders
39
No. of Employees
3,059
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
183,593,434

BMRN Share Price Performance

Latest News for BMRN

Upcoming Events for BMRN

Q4 2021 Biomarin Pharmaceutical Inc Earnings Release

Q1 2022 Biomarin Pharmaceutical Inc Earnings Release

Biomarin Pharmaceutical Inc Annual Shareholders Meeting

Similar to BMRN

Picture of Abcam logo

Abcam

us flag iconNASDAQ Global Select Market

Picture of Amgen logo

Amgen

us flag iconNASDAQ Global Select Market

Picture of Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Amryt Pharma logo

Amryt Pharma

us flag iconNASDAQ Global Select Market

Picture of Anika Therapeutics logo

Anika Therapeutics

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email